ProKidney
The development of a cell therapy candidate that has the potential to improve the lives of patients with chronic kidney disease.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 127 % | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (208542 %) | (103536 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (80508 %) | (46748 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | 167984 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
ProKidney is a late clinical-stage biotech company dedicated to revolutionizing the treatment of Chronic Kidney Disease (CKD). The company is pioneering a novel cell therapy called rilparencel, which aims to preserve kidney function in patients with advanced CKD. This innovative approach could potentially delay or even eliminate the need for dialysis, a life-altering procedure that many CKD patients currently face as their only option.
ProKidney operates in the healthcare and biotechnology market, focusing specifically on the treatment of CKD, a condition affecting over 35 million adults in the United States alone. Each year, approximately 135,000 of these patients progress to dialysis, underscoring the urgent need for new therapeutic options.
The company primarily serves patients suffering from CKD, offering them a groundbreaking treatment that could significantly improve their quality of life. By targeting a specific and underserved segment of the healthcare market, ProKidney aims to fill a critical gap in CKD treatment.
ProKidney's business model revolves around the development and commercialization of its lead product candidate, rilparencel. The company is currently in the late stages of clinical trials, and early data suggests that rilparencel has the potential to preserve kidney function effectively. Once approved, ProKidney plans to generate revenue through the sale and distribution of rilparencel to healthcare providers and directly to patients.
The company makes money by developing and eventually selling its proprietary cell therapy. As rilparencel progresses through clinical trials and gains regulatory approval, ProKidney will likely enter into partnerships with healthcare providers and insurance companies to ensure broad access to its treatment.
In summary, ProKidney is at the forefront of developing a first-in-class cell therapy for CKD, aiming to transform the lives of millions of patients by offering a viable alternative to dialysis.
Keywords: CKD, cell therapy, rilparencel, biotech, healthcare, dialysis, kidney function, clinical trials, innovation, treatment.